JP6506390B2 - キノリノン系化合物及びその薬物への使用 - Google Patents
キノリノン系化合物及びその薬物への使用 Download PDFInfo
- Publication number
- JP6506390B2 JP6506390B2 JP2017512046A JP2017512046A JP6506390B2 JP 6506390 B2 JP6506390 B2 JP 6506390B2 JP 2017512046 A JP2017512046 A JP 2017512046A JP 2017512046 A JP2017512046 A JP 2017512046A JP 6506390 B2 JP6506390 B2 JP 6506390B2
- Authority
- JP
- Japan
- Prior art keywords
- group
- methyl
- independently
- mmol
- hydroxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 *c(c(*)c1*)c(*)c(C(O)=C2C(NCC(O)=O)=O)c1N(*)C2=O Chemical compound *c(c(*)c1*)c(*)c(C(O)=C2C(NCC(O)=O)=O)c1N(*)C2=O 0.000 description 1
- UZGBENGFNVWPQF-UHFFFAOYSA-N CN(c(c(C(O)=C1C(NCC(O)=O)=O)c2)ccc2Oc2ccccc2)C1=O Chemical compound CN(c(c(C(O)=C1C(NCC(O)=O)=O)c2)ccc2Oc2ccccc2)C1=O UZGBENGFNVWPQF-UHFFFAOYSA-N 0.000 description 1
- YWAUYPYFFKKBFV-UHFFFAOYSA-N CN(c(cc(cc1)Oc2ccncc2)c1C(O)=C1C(NCC(O)=O)=O)C1=O Chemical compound CN(c(cc(cc1)Oc2ccncc2)c1C(O)=C1C(NCC(O)=O)=O)C1=O YWAUYPYFFKKBFV-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
- C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Quinoline Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410442574.4 | 2014-09-02 | ||
| CN201410442574 | 2014-09-02 | ||
| PCT/CN2015/088799 WO2016034108A1 (zh) | 2014-09-02 | 2015-09-01 | 喹啉酮类化合物及其应用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017525737A JP2017525737A (ja) | 2017-09-07 |
| JP2017525737A5 JP2017525737A5 (enExample) | 2018-06-14 |
| JP6506390B2 true JP6506390B2 (ja) | 2019-04-24 |
Family
ID=55417512
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017512046A Active JP6506390B2 (ja) | 2014-09-02 | 2015-09-01 | キノリノン系化合物及びその薬物への使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US10065928B2 (enExample) |
| EP (1) | EP3190104B1 (enExample) |
| JP (1) | JP6506390B2 (enExample) |
| CN (1) | CN105384687B (enExample) |
| AU (1) | AU2015311333B2 (enExample) |
| CA (1) | CA2959688C (enExample) |
| ES (1) | ES2898476T3 (enExample) |
| WO (1) | WO2016034108A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106146414A (zh) * | 2016-07-07 | 2016-11-23 | 浙江大学 | 喹唑啉二酮类衍生物及其制备方法和用途 |
| CN108069952B (zh) * | 2016-11-08 | 2022-09-27 | 广东东阳光药业有限公司 | 喹啉酮类化合物及其在药物中应用 |
| CN108069957B (zh) * | 2016-11-09 | 2022-11-04 | 广东东阳光药业有限公司 | 脯氨酰羟化酶抑制剂及其用途 |
| CN108285460A (zh) * | 2017-01-09 | 2018-07-17 | 南京圣和药业股份有限公司 | 一种egfr激酶抑制剂的药用盐及其制备方法与用途 |
| JP6999469B2 (ja) * | 2018-03-28 | 2022-01-18 | 東京応化工業株式会社 | 水素バリア剤、水素バリア膜形成用組成物、水素バリア膜、水素バリア膜の製造方法、及び電子素子 |
| JP7680447B2 (ja) * | 2019-11-28 | 2025-05-20 | サンシャイン・レイク・ファーマ・カンパニー・リミテッド | キノリノン系化合物の結晶形及びその用途 |
| CN111269178A (zh) * | 2019-11-28 | 2020-06-12 | 南北兄弟药业投资有限公司 | 喹啉酮类化合物的晶型 |
| CN111269176A (zh) * | 2019-11-28 | 2020-06-12 | 南北兄弟药业投资有限公司 | 喹啉酮类化合物的晶型 |
| CN111269177B (zh) * | 2019-11-28 | 2023-05-09 | 广东东阳光药业有限公司 | 喹啉酮类化合物的晶型 |
| CN115010663A (zh) * | 2021-03-05 | 2022-09-06 | 广东东阳光药业有限公司 | 喹啉酮类化合物的晶型及其用途 |
| CN115010664A (zh) * | 2021-03-05 | 2022-09-06 | 广东东阳光药业有限公司 | 喹啉酮类化合物的晶型及其用途 |
| WO2022184159A1 (zh) * | 2021-03-05 | 2022-09-09 | 广东东阳光药业有限公司 | 喹啉酮类化合物的晶型及其用途 |
| CN114989085B (zh) * | 2022-05-23 | 2023-11-24 | 安徽医科大学 | 一种芳基内酰胺环类化合物、药物组合物及其应用 |
| CN117159549B (zh) * | 2023-10-11 | 2025-02-14 | 中国药科大学 | 一种酯类化合物的应用 |
| WO2026021503A1 (zh) * | 2024-07-24 | 2026-01-29 | 合肥医工医药股份有限公司 | 喹啉衍生物及其制备方法和用途 |
Family Cites Families (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103145616B (zh) | 2003-06-06 | 2015-09-30 | 菲布罗根有限公司 | 含氮杂芳基化合物及其在增加内源性促红细胞生成素中的用途 |
| EP1849465A4 (en) * | 2005-02-18 | 2008-12-24 | Takeda Pharmaceutical | AGENS TO CONTROL THE FUNCTION OF THE GPR34 RECEPTOR |
| US8703795B2 (en) | 2005-03-02 | 2014-04-22 | Fibrogen, Inc. | Thienopyridine compounds, and methods of use thereof |
| DE102005019712A1 (de) | 2005-04-28 | 2006-11-09 | Bayer Healthcare Ag | Dipyridyl-dihydropyrazolone und ihre Verwendung |
| WO2007038571A2 (en) * | 2005-09-26 | 2007-04-05 | Smithkline Beecham Corporation | Prolyl hydroxylase antagonists |
| AU2006326662B2 (en) * | 2005-12-09 | 2011-07-28 | Amgen Inc. | Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, and compositions, and uses thereof |
| CN102351791B (zh) | 2006-01-27 | 2014-10-29 | 菲布罗根有限公司 | 使低氧诱导因子(hif)稳定的氰基异喹啉化合物 |
| PE20071020A1 (es) * | 2006-03-07 | 2007-12-11 | Smithkline Beecham Corp | Compuestos derivados de glicina n-sustituidos como inhibidores de prolil hidroxilasa |
| AU2007234408B2 (en) | 2006-04-04 | 2011-05-19 | Fibrogen, Inc. | Pyrrolo- and thiazolo-pyridine compounds as HIF modulators |
| JP2009537558A (ja) | 2006-05-16 | 2009-10-29 | スミスクライン・ビーチャム・コーポレイション | プロリルヒドロキシラーゼ阻害剤 |
| TWI394747B (zh) | 2006-06-23 | 2013-05-01 | Smithkline Beecham Corp | 脯胺醯基羥化酶抑制劑 |
| NZ623002A (en) | 2006-06-26 | 2015-08-28 | Akebia Therapeutics Inc | Prolyl hydroxylase inhibitors and methods of use |
| DE102006050516A1 (de) | 2006-10-26 | 2008-04-30 | Bayer Healthcare Ag | Substituierte Dihydropyrazolone und ihre Verwendung |
| US8048892B2 (en) | 2006-12-18 | 2011-11-01 | Amgen Inc. | Azaquinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof |
| WO2008076427A2 (en) | 2006-12-18 | 2008-06-26 | Amgen Inc. | Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof |
| TW200845994A (en) | 2007-01-12 | 2008-12-01 | Smithkline Beecham Corp | N-substituted glycine derivatives: prolyl hydroxylase inhibitors |
| CL2008000066A1 (es) | 2007-01-12 | 2008-08-01 | Smithkline Beecham Corp | Compuestos derivados de (5-hidroxi-3-oxo-2,3-dihidropiridazina-4-carbonil)glicina, inhibidores de hif prolil hidroxilasas; procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de la anem |
| ES2446418T3 (es) | 2007-04-18 | 2014-03-07 | Amgen, Inc | Derivados de indanona que inhiben la prolil hidroxilasa |
| WO2008130527A1 (en) | 2007-04-18 | 2008-10-30 | Merck & Co., Inc. | Novel 1,8-naphthyridine compounds |
| EP2142509B1 (en) | 2007-04-18 | 2013-12-04 | Amgen, Inc | Quinolones and azaquinolones that inhibit prolyl hydroxylase |
| US8030346B2 (en) | 2007-05-04 | 2011-10-04 | Amgen Inc. | Heterocyclic quinolone derivatives that inhibit prolyl hydroxylase activity |
| US20110028507A1 (en) | 2007-08-10 | 2011-02-03 | Crystalgenomics, Inc. | Pyridine derivatives and methods of use thereof |
| WO2009039322A1 (en) | 2007-09-19 | 2009-03-26 | Smithkline Beecham Corporation | Prolyl hydroxylase inhibitors |
| WO2009039323A1 (en) | 2007-09-19 | 2009-03-26 | Smithkline Beecham Corporation | Prolyl hydroxylase inhibitors |
| WO2009039321A1 (en) | 2007-09-19 | 2009-03-26 | Smithkline Beecham Corporation | Prolyl hydroxylase inhibitors |
| WO2009049112A1 (en) | 2007-10-10 | 2009-04-16 | Smithkline Beecham Corporation | Prolyl hydroxylase inhibitors |
| JP2011505367A (ja) | 2007-11-30 | 2011-02-24 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | プロリルヒドロキシラーゼ阻害剤 |
| WO2009073497A2 (en) | 2007-11-30 | 2009-06-11 | Smithkline Beecham Corporation | Prolyl hydroxylase inhibitors |
| WO2009073669A1 (en) | 2007-12-03 | 2009-06-11 | Fibrogen, Inc. | Isoxazolopyridine derivatives for use in the treatment of hif-mediated conditions |
| EP2240178A4 (en) | 2007-12-19 | 2011-10-26 | Glaxosmithkline Llc | PROLYLHYDROXYLASEHEMMER |
| US8952160B2 (en) | 2008-01-11 | 2015-02-10 | Fibrogen, Inc. | Isothiazole-pyridine derivatives as modulators of HIF (hypoxia inducible factor) activity |
| US8324405B2 (en) | 2008-02-05 | 2012-12-04 | Fibrogen, Inc. | Chromene derivatives and use thereof as HIF hydroxylase activity inhibitors |
| CN101951776A (zh) | 2008-02-25 | 2011-01-19 | 默沙东公司 | 四氢-1h-吡咯稠合吡啶酮 |
| CN101951775A (zh) | 2008-02-25 | 2011-01-19 | 默沙东公司 | 四氢噻吩并吡啶 |
| CA2716798A1 (en) | 2008-02-25 | 2009-09-03 | Merck Sharp & Dohme Corp. | Tetrahydrofuropyridones |
| PT2294066E (pt) | 2008-04-28 | 2014-11-21 | Janssen Pharmaceutica Nv | Benzoimidazoles como inibidores da prolil-hidroxilase |
| WO2009134847A1 (en) | 2008-04-30 | 2009-11-05 | Smithkline Beecham Corporation | Prolyl hydroxylase inhibitors |
| WO2009134850A1 (en) | 2008-04-30 | 2009-11-05 | Smithkline Beecham Corporation | Prolyl hydroxylase inhibitors |
| US20110098324A1 (en) | 2008-06-25 | 2011-04-28 | Brackley Iii James A | Prolyl hydroxylase inhibitors |
| CN102264740B (zh) | 2008-08-20 | 2014-10-15 | 菲布罗根有限公司 | 一种吡咯[1,2-b]哒嗪衍生物及其作为hif调节剂的用途 |
| WO2010022307A2 (en) | 2008-08-21 | 2010-02-25 | Smithkline Beecham Corporation | Prolyl hydroxylase inhibitors |
| WO2010025087A1 (en) | 2008-08-25 | 2010-03-04 | Smithkline Beecham Corporation | Prolyl hydroxylase inhibitors |
| WO2010056767A1 (en) | 2008-11-14 | 2010-05-20 | Fibrogen, Inc. | Thiochromene derivatives as hip hydroxylase inhibitors |
| JP5643233B2 (ja) | 2009-02-10 | 2014-12-17 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプＪａｎｓｓｅｎ Ｐｈａｒｍａｃｅｕｔｉｃａ Ｎａａｍｌｏｚｅ Ｖｅｎｎｏｏｔｓｃｈａｐ | プロリルヒドロキシラーゼ阻害物質としてのキナゾリノン |
| IN2012DN00549A (enExample) | 2009-07-15 | 2015-06-12 | Zhejiang Beta Pharma Inc | |
| US8283465B2 (en) | 2009-07-17 | 2012-10-09 | Japan Tobacco Inc. | Triazolopyridine compound, and action thereof as prolyl hydroxylase inhibitor or erythropoietin production-inducing agent |
| WO2011048611A1 (en) | 2009-10-07 | 2011-04-28 | Torrent Pharmaceuticals Limited | Novel fused pyridazine derivatives |
| TWI500623B (zh) | 2009-10-13 | 2015-09-21 | Torrent Pharmaceuticals Ltd | 新穎稠合噻唑及噁唑嘧啶酮 |
| WO2011056725A1 (en) | 2009-11-05 | 2011-05-12 | Crystalgenomics, Inc. | Pyridine derivatives and methods of use thereof |
| US8541430B2 (en) | 2009-11-27 | 2013-09-24 | Torrent Pharmaceuticals Limited | Fused thiazolo and oxazolo pyrimidinones |
| EP2603502B1 (en) | 2010-08-13 | 2014-07-30 | Janssen Pharmaceutica, N.V. | 4-aminoquinazolin-2-yl-1-pyrrazole-4-carboxylic acid compounds as prolyl hydroxylase inhibitors |
| EP2670750B1 (en) | 2011-02-02 | 2016-09-14 | Fibrogen, Inc. | Naphthyridine derivatives as inhibitors of hypoxia inducible factor |
| NO2686520T3 (enExample) | 2011-06-06 | 2018-03-17 | ||
| CN103717214A (zh) | 2011-06-06 | 2014-04-09 | 阿克比治疗有限公司 | 用于稳定低氧诱导因子-2α作为治疗癌症的方法的化合物和组合物 |
| EP2736892A4 (en) | 2011-07-29 | 2015-03-18 | Beijing Betta Pharmaceuticals Co Ltd | STABLE POLYMORPHIC FORMS OF A CONNECTION AS HYPOXIEMIMETICS AND USES THEREOF |
| WO2013134660A1 (en) | 2012-03-09 | 2013-09-12 | Fibrogen, Inc. | 4 -hydroxy- isoquinoline compounds as hif hydroxylase inhibitors |
| US8883823B2 (en) | 2012-07-16 | 2014-11-11 | Fibrogen, Inc. | Crystalline forms of a prolyl hydroxylase inhibitor |
| SG11201500234YA (en) | 2012-07-16 | 2015-02-27 | Fibrogen Inc | Process for making isoquinoline compounds |
| KR102018409B1 (ko) | 2012-07-30 | 2019-09-04 | 다이쇼 세이야꾸 가부시끼가이샤 | 부분적으로 포화된 질소 함유 복소환 화합물 |
| JPWO2014030716A1 (ja) | 2012-08-23 | 2016-08-08 | 田辺三菱製薬株式会社 | ピラゾロピリミジン化合物 |
| AP2015008502A0 (en) * | 2012-12-24 | 2015-06-30 | Cadila Healthcare Ltd | Novel quinolone derivatives |
| SG10202009266PA (en) | 2013-01-24 | 2020-10-29 | Fibrogen Inc | Crystalline forms of {[1-cyano-5-(4-chlorophenoxy)-4-hydroxy-isoquinoline-3-carbonyl]-amino}-acetic acid |
-
2015
- 2015-09-01 CA CA2959688A patent/CA2959688C/en active Active
- 2015-09-01 AU AU2015311333A patent/AU2015311333B2/en active Active
- 2015-09-01 US US15/502,499 patent/US10065928B2/en active Active
- 2015-09-01 ES ES15837609T patent/ES2898476T3/es active Active
- 2015-09-01 JP JP2017512046A patent/JP6506390B2/ja active Active
- 2015-09-01 CN CN201510557206.9A patent/CN105384687B/zh active Active
- 2015-09-01 EP EP15837609.5A patent/EP3190104B1/en active Active
- 2015-09-01 WO PCT/CN2015/088799 patent/WO2016034108A1/zh not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| JP2017525737A (ja) | 2017-09-07 |
| ES2898476T3 (es) | 2022-03-07 |
| CA2959688A1 (en) | 2016-03-10 |
| EP3190104A4 (en) | 2018-04-11 |
| CN105384687B (zh) | 2018-05-01 |
| EP3190104A1 (en) | 2017-07-12 |
| CA2959688C (en) | 2024-02-27 |
| EP3190104B1 (en) | 2021-10-27 |
| US20170247332A1 (en) | 2017-08-31 |
| AU2015311333B2 (en) | 2017-11-16 |
| US10065928B2 (en) | 2018-09-04 |
| CN105384687A (zh) | 2016-03-09 |
| AU2015311333A1 (en) | 2017-02-16 |
| WO2016034108A1 (zh) | 2016-03-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2015311333B2 (en) | Quinolinone compound and use thereof | |
| EP3265445B1 (en) | Lysyl oxidase-like 2 inhibitors and uses thereof | |
| WO2024008178A1 (zh) | Kras g12d抑制剂及其在医药上的应用 | |
| RU2686323C2 (ru) | Новые соединения и композиции для ингибирования fasn | |
| WO2019134539A1 (zh) | 二氢吡唑酮并嘧啶类化合物及其制备方法和用途 | |
| WO2018149284A1 (zh) | 激酶抑制剂及其制备方法和用途 | |
| TWI833046B (zh) | 吡咯醯胺類化合物及其用途 | |
| WO2023138541A1 (zh) | 吡啶酰胺类parp抑制剂、及其制备方法和医药用途 | |
| WO2023088408A1 (zh) | 选择性parp1抑制剂及其应用 | |
| WO2020221038A1 (zh) | 苯并噻吩类化合物及其制备方法和用途 | |
| CA2923269A1 (en) | Cycloalkyl acid derivative, preparation method thereof, and pharmaceutical application thereof | |
| CN112851647B (zh) | 布雷菲德菌素a衍生物及其制备方法和用途 | |
| CN116615189A (zh) | 新型细胞代谢调节化合物及其用于治疗病毒疾病的用途 | |
| WO2023061406A1 (zh) | 含三并环结构的parp抑制剂、及其制备方法和医药用途 | |
| WO2024212670A1 (zh) | 乙烯基吡喃酮类化合物及其在治疗阿尔茨海默病中的应用 | |
| WO2019084300A1 (en) | TREATMENT OF GLIOBLASTOMA WITH FASN INHIBITORS | |
| CN107108525A (zh) | 用作Lp‑PLA2抑制剂的嘧啶酮类化合物及其药物组合物 | |
| CN110156674A (zh) | 一种作为吲哚胺-2,3-双加氧酶抑制剂的螺环化合物 | |
| CN108069952B (zh) | 喹啉酮类化合物及其在药物中应用 | |
| CN108069957B (zh) | 脯氨酰羟化酶抑制剂及其用途 | |
| WO2022214937A1 (en) | Substituted tetracyclic carboxylic acids, analogues thereof, and methods using same | |
| WO2022063197A1 (zh) | 一种嘧啶甲酰胺类化合物及其应用 | |
| WO2022116968A1 (zh) | 一种新型n-杂环bet溴结构域抑制剂、其制备方法及医药用途 | |
| WO2011124093A1 (zh) | 双环喹诺酮类化合物及其制备和应用 | |
| TW202540096A (zh) | 靶向降解雄激素受體的雙功能嵌合體的雜環化合物及其用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180501 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20180501 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20181213 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20181218 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190307 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20190319 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20190328 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6506390 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |